clinical trial · NCT04708834
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
Biohaven Pharmaceuticals, Inc.·phase3·terminated·n = 772
Obsessive Compulsive DisorderTroriluzole (BHV-4157)
brief summary
The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compulsive disorder (OCD).
started
Mar 30, 2021
primary completion
Feb 13, 2026
completion
Feb 13, 2026
last updated
Feb 25, 2026
official title
A Multicenter, Long-Term Open-Label Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol